Monday, 25 August 2008

Stop smoking pill 'quit success'


A controversial pill is boosting the success of smokers in England in kicking the habit, NHS figures suggest.



One in seven people trying to quit are using Champix, according to the first figures published since the stop smoking drug was licensed in 2006.



And NHS Information Centre data showed 63% of people were successful last year at the four-week mark compared to half using nicotine replacement therapy.



Champix has come under scrutiny over reports it causes suicidal feelings.



The Medicines and Healthcare Products Regulatory Agency says it is "closely" monitoring the drug after almost 3,000 reports of adverse reactions.

















So far in that respect have been more than 200 reports of suicidal thoughts in patients taking Champix.



And more than than 350 reports of depression, although these have mainly involved patients world Health Organization had an underlying psychiatrical illness.



The drug is unusual as it both stimulates and blocks specific nicotinic receptors in the brain.



By stimulating the receptor it is thought to mimicker the personal effects of nicotine to reduce cravings.



At the same time, it part blocks the receptor preventing nicotine from binding to it, resulting in a weaker response in people who present in to temptation and have a cigarette.



Trials suggested around 44% of smokers give up after taking the dose twice a day for 12 weeks, compared with 18% of those apt a placebo and 30% of those taking some other major anti-smoking drug, bupropion.



Smoking ban



The latest figures show that in 2007-8 - the first year since the smoke ban was introduced - there was a 13% increase to 680,000 in the number of people stage setting a depart date.



There was also a 10% uprise to 350,800 in the number of people who had stuck to their attempts to lay off after four weeks.



NHS Stop Smoking Services spent most �61 1000000 in the past year on serving people to quit - nearly �10 million higher than the year before.



Health minister Ann Keen aforesaid she was delighted with the increase in people successfully quitting smoking.



"I'd like to take aim this opportunity to tell congratulations to all those who have made such positive efforts to recoil the riding habit - selfsame well done.



"This shows that the investments that we are qualification in helping smokers to quit are having a positive impact."




More info

Friday, 15 August 2008

Risk Assessment Plays Key Role In Long-Term Treatment Of Breast Cancer

� Breast cancer patients and their physicians may make more informed, long-run treatment decisions using danger assessment strategies to help determine chance of recurrence, a research team light-emitting diode by scientists at The University of Texas M. D. Anderson Cancer Center reported in the Aug. 12 on-line issue of the Journal of the National Cancer Institute.


The 2,838 women studied were diagnosed with Stage I through III breast cancers and had been treated with adjuvant systemic therapy (AST), such as chemotherapy and or estrogen antagonist between 1985 and 2001, and were in the M. D. Anderson Tumor Registry. The patients in the study were five years from the get going of their AST and were cancer-free. The researchers calculated the residual or remaining danger of recurrence from the benchmark of five eld from the start of AST and determined the factors that contributed to a higher residual risk of exposure of return.


"Understandably, one of the most common questions posed by breast cancer survivors is 'What are the chances of it coming back?'," said the study's jumper cable author, Abenaa Brewster, M.D., assistant professor in M. D. Anderson's Department of Clinical Cancer Prevention. "Now we canful tell some women within a certain percentage their future risk of recurrence and clinicians may be able to make more than informed decisions regarding prescription of prolonged adjuvant ductless gland therapy."


Data analysis revealed that 89 percent of the study populations did not know a recurrence at

Thursday, 7 August 2008

Sierra Maestra

Sierra Maestra   
Artist: Sierra Maestra

   Genre(s): 
Latin
   



Discography:


Dundunbanza   
 Dundunbanza

   Year: 1994   
Tracks: 9




Havana-based base Sierra Maestra is i of the foremost bands playacting the Cuban word style, which enjoyed its height of popularity in the '20s and '30s. Though parole experienced significant revival and renewed outside interest thanks to the late-'90s Buena Vista Social Club phenomenon, Sierra Maestra gave the music a new rent on liveliness as other as the late '70s. Headed by Juan d'Marcos González, the nine-piece rig came in concert in 1976 for a operation at the University of Havana, the musicians' alma mater. Utilizing traditional